IEH Corporation – $3.6M in Orders; Diversifying Sales via Medical Industry
...
X4 Pharmaceuticals
[stock_market_widget type=”inline-label” template=”indicator” assets=”XFOR” realtime=”true” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”XFOR” fields=”market_cap,enterprise_value,pe_ratio,forward_pe_ratio,peg_ratio,price_to_sales_trailing_12_months,price_book,enterprise_revenue,enterprise_ebitda” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”XFOR” fields=”volume,open,previous_close,range,52_week_range,beta,target_high_price,shares_outstanding,shares_float” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”chart” template=”line” assets=”XFOR” range=”1y” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#000000″ range_selector=”true” axes=”true” cursor=”true” style=”font-size: 14px” api=”yahoo-finance”]
Description
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI in its first indication.
Financial Highlights
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”XFOR” fields=”profit_margin,operating_margin,return_on_assets,return_on_equity,total_revenue,revenue_per_share,revenue_growth,gross_profit,ebitda,net_income_to_common,quarter_earnings_growth,total_cash,total_cash_per_share,total_debt,operating_cashflow” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
Trading Information
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”XFOR” fields=”52_week_low_change_pct,52_week_high,52_week_low,50_day_average,200_day_average,average_volume,average_volume_10_days,shares_outstanding,shares_float,held_percent_insiders,held_percent_institutions,shares_short,short_ratio,annual_dividend_rate,annual_dividend_yield” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
